Pharmaceutical Industry discussion, review, analysis, news and information. |
« Raptor Pharmaceutical Inc. Entered Research Collaboration with Stanford University to Study Use of NeuroTrans™ (Therapeutics Delivery across the Blood-Brain Barrier) | Main | FDA Warning: Don’t Drink High-Strength Hydrogen Peroxide (even) for Medicinal Use »
|
Aug 4
|
 With this approval, Betaferon becomes the highest-dose highest-frequency therapy approved for the treatment of the earliest stages of MS in Canada. The approval provides an important treatment option for patients to reduce the risk of developing clinically definite MS (CDMS), and the potential to delay the progression of the disease. A similar supplemental biologics license application (sBLA) has also been applied to the US FDA in February, and is awaiting approval. Source: Schering |
TrackBack URL for this entry:
« Raptor Pharmaceutical Inc. Entered Research Collaboration with Stanford University to Study Use of NeuroTrans™ (Therapeutics Delivery across the Blood-Brain Barrier) | Main | FDA Warning: Don’t Drink High-Strength Hydrogen Peroxide (even) for Medicinal Use »
Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!
BIZZlogos - Add your logo - free link to your site| View Network Map Network Feed List (OPML) Know More Media Network Feed |
PharmaGazette is a member of the Know More Media network of business related blogs.
Here are some current headlines from some of our business publications:
ProductivityGoal | CallCenterScript |
AdHurl | TheBizofKnowledge |
LandingTheDeal | CustomersAreAlways |
HealthCareVox | BrainBasedBusiness |
TheInsurancePolicy | MarketingBlurb |
Write for us About us Contact Advertise Privacy Disclaimer
This weblog is licensed under a Creative Commons License.
Comment Preview